Blocking agents of EDRF effect or formation for the treatment of

Details Blocking agents of EDRF effect or formation for the treatment of Blocking agents of EDRF effect or formation for the treatment of

1990-12-19

1992-01-14

Friedman, Stanley J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ortho-hydroxybenzoic acid or derivative doai

514529, 514551, 514420, 514921, A61K 3122, A61K 3140, A61K 31215, A61K 31615

Patent

active

050811487

ABSTRACT:
The invention relates to a therapeutical composition of matter for the treatment by perfusion of shock states comprising as an essential ingredient therein, an effective amount either, of a compound of the formula: ##STR1## wherein R.sub.1 and R.sub.4 stant for H or CH.sub.3 or C.sub.2 H.sub.5,

REFERENCES:
BIOSIS #88127938, Aisaka et al L-Arginine availability determines the duration of acetylcholine-induced systemic vasodilation in vivo.
Vallance et al. BIOSIS #89074491, Nitric oxide synthesized from L-arginine mediates endothelium dependent dilation in human vein in-vivo.

Affiliated with

Also associated with

Rating

Blocking agents of EDRF effect or formation for the treatment of does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Blocking agents of EDRF effect or formation for the treatment of, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blocking agents of EDRF effect or formation for the treatment of will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-541967